KALV vs. ABUS, ALIM, MGTA, BCRX, RCKT, CPRX, GLPG, ZLAB, NAMS, and KROS
Should you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Arbutus Biopharma (ABUS), Alimera Sciences (ALIM), Magenta Therapeutics (MGTA), BioCryst Pharmaceuticals (BCRX), Rocket Pharmaceuticals (RCKT), Catalyst Pharmaceuticals (CPRX), Galapagos (GLPG), Zai Lab (ZLAB), NewAmsterdam Pharma (NAMS), and Keros Therapeutics (KROS). These companies are all part of the "medical" sector.
KalVista Pharmaceuticals (NASDAQ:KALV) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment.
KalVista Pharmaceuticals has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -572.81%. Arbutus Biopharma's return on equity of -62.68% beat KalVista Pharmaceuticals' return on equity.
KalVista Pharmaceuticals has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500.
In the previous week, Arbutus Biopharma had 3 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 6 mentions for Arbutus Biopharma and 3 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.83 beat Arbutus Biopharma's score of 0.70 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media.
Arbutus Biopharma has higher revenue and earnings than KalVista Pharmaceuticals. Arbutus Biopharma is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Arbutus Biopharma received 96 more outperform votes than KalVista Pharmaceuticals when rated by MarketBeat users. However, 73.93% of users gave KalVista Pharmaceuticals an outperform vote while only 70.83% of users gave Arbutus Biopharma an outperform vote.
KalVista Pharmaceuticals presently has a consensus price target of $25.00, suggesting a potential upside of 114.22%. Arbutus Biopharma has a consensus price target of $4.33, suggesting a potential upside of 28.97%. Given KalVista Pharmaceuticals' higher probable upside, equities analysts clearly believe KalVista Pharmaceuticals is more favorable than Arbutus Biopharma.
43.8% of Arbutus Biopharma shares are owned by institutional investors. 12.3% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Arbutus Biopharma beats KalVista Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get KalVista Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KalVista Pharmaceuticals Competitors List
Related Companies and Tools
